The cost-effectiveness of a controversial test promoted as a multicancer early detection (MCED) tool from a single blood sample has been scrutinised in an investigation by the BMJ. Grail’s Galleri test was claimed to pick up more than 50 cancer types including tumours that are typically difficult to detect early…
